Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nephrotoxicity Biomarker Prepares For Clinic After FDA Blesses Animal Test

Executive Summary

The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial

You may also be interested in...



Drug Development Tools: Passed And Future

FDA has qualified a total of eight biomarkers submitted by two different consortia through a process that has followed, to varying degrees, the route described in the recently released draft guidance on drug development tool qualification.

BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development

BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.

BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development

BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel